The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment

UnknownOBSERVATIONAL
Enrollment

204

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Chronic Hepatitis B
Interventions
DRUG

TMF

switch ETV to TMF

Trial Locations (13)

400010

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

NOT_YET_RECRUITING

Chongqing University Three Gorges Central Hospital, Chongqing

Unknown

NOT_YET_RECRUITING

Affiliated Hospital of Guangxi Medical University, Guangxi

NOT_YET_RECRUITING

Hepatobiliary disease of Jilin Province, Jilin

NOT_YET_RECRUITING

The First People's Hospital of Yunnan Province, Kunming

NOT_YET_RECRUITING

the Second People's Hospital of Yunnan Province, Kunming

NOT_YET_RECRUITING

Nanjing Second Hospital, Nanjing

RECRUITING

The Second Hospital of Ningbo, Ningbo

RECRUITING

Shanghai East Hospital, Shanghai

NOT_YET_RECRUITING

Shuguang Hospital, Shanghai, China., Shanghai

NOT_YET_RECRUITING

The Sixth People's Hospital of Shenyang, Shenyang

NOT_YET_RECRUITING

The First People's Hospital of Taicang, Taicang

NOT_YET_RECRUITING

The Fourth People's Hospital of Zibo, Zibo

All Listed Sponsors
collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

lead

The Second Affiliated Hospital of Chongqing Medical University

OTHER

NCT05755776 - The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment | Biotech Hunter | Biotech Hunter